Condition
Pediatric AML
Total Trials
4
Recruiting
2
Active
2
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Early P 1 (1)
P 1 (1)
P 2 (1)
P 3 (1)
Trial Status
Recruiting2
Completed2
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07059975Early Phase 1Recruiting
UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML
NCT06211452Phase 3Completed
Comparison of Consolidation Strategies for Pediatric Patients With Acute Myeloid Leukemia
NCT05313958Phase 2Recruiting
Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children
NCT03455140Phase 1Completed
A Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100)
Showing all 4 trials